Health Care & Life Sciences » Pharmaceuticals | DelMar Pharmaceuticals Inc.

DelMar Pharmaceuticals Inc. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2012
2013
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
-
-
10.30
16.70
24.50
Gross Income
-
-
-
10.30
16.70
24.50
SG&A Expense
18.90
6,295.00
4,724.70
6,203.70
8,304.10
11,150.10
EBIT
18.90
6,295.00
4,724.70
-
8,320.80
11,174.70
Unusual Expense
-
1,389.20
402.00
2,637.10
246.00
60.10
Non Operating Income/Expense
-
601.00
23.40
13.80
7.40
57
Interest Expense
-
8.00
2.10
-
-
-
Pretax Income
18.90
8,290.70
4,347.80
8,864.90
8,081.80
11,138.30
Consolidated Net Income
18.90
8,290.70
4,347.80
8,864.90
8,081.80
11,138.30
Net Income
18.90
8,290.70
4,347.80
8,864.90
8,081.80
11,138.30
Net Income After Extraordinaries
18.90
8,290.70
4,347.80
8,864.90
8,081.80
11,138.30
Net Income Available to Common
18.90
8,290.70
4,347.80
9,103.20
8,872.20
11,314.50
EPS (Basic)
0.01
1.12
0.44
0.83
0.74
5.40
Basic Shares Outstanding
2,657.50
7,416.80
9,516.90
10,948.50
12,047.10
2,086.10
EPS (Diluted)
0.01
1.12
0.46
0.83
0.74
5.42
Diluted Shares Outstanding
2,657.50
7,416.80
9,516.90
10,948.50
12,047.10
2,086.10
EBITDA
18.90
6,295.00
4,724.70
6,203.70
8,304.20
11,150.10
Non-Operating Interest Income
-
2.50
0.40
0.10
0.50
33.20
Preferred Dividends
-
-
-
238.30
790.50
176.20

About DelMar Pharmaceuticals

View Profile
Address
999 West Broadway
Vancouver British Columbia V5Z 1K5
Canada
Employees -
Website http://www.delmarpharma.com
Updated 07/08/2019
DelMar Pharmaceuticals, Inc. is a clinical and commercial stage drug development company, which focuses on the research and development of drugs for the treatment of cancer. It offers VAL-083; drug discovery research; as well as patents and intellectual property. The company was founded by Jeffrey A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.